Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study

Purpose: In current radiotherapy (RT) planning and delivery, population-based dose-volume constraints are used to limit the risk of toxicity from incidental irradiation of organs at risks (OARs). However, weighing tradeoffs between target coverage and doses to OARs (or prioritizing different OARs) in a quantitative way for each patient is challenging. We introduce a novel RT planning approach for patients with mediastinal Hodgkin lymphoma (HL) that aims to maximize overall outcome for each patient by optimizing on tumor control and mortality from late effects simultaneously.Material and Methods: We retrospectively analyzed 34 HL patients treated with conformal RT (3DCRT). We used published data to model recurrence and radiation-induced mortality from coronary heart disease and secondary lung and breast cancers. Patient-specific doses to the heart, lung, breast, and target were incorporated in the models as well as age, sex, and cardiac risk factors (CRFs). A preliminary plan of candidate beams was created for each patient in a commercial treatment planning system. From these candidate beams, outcome-optimized (O-OPT) plans for each patient were created with an in-house optimization code that minimized the individual risk of recurrence and mortality from late effects. O-OPT plans were compared to VMAT plans and clinical 3DCRT plans.Results: O-OPT plans generally had the lowest risk, followed by the clinical 3DCRT plans, then the VMAT plans with the highest risk with median (maximum) total risk values of 4.9 (11.1), 5.1 (17.7), and 7.6 (20.3)%, respectively (no CRFs). Compared to clinical 3DCRT plans, O-OPT planning reduced the total risk by at least 1% for 9/34 cases assuming no CRFs and 11/34 cases assuming presence of CRFs.Conclusions: We developed an individualized, outcome-optimized planning technique for HL. Some of the resulting plans were substantially different from clinical plans. The results varied depending on how risk models were defined or prioritized.

RhoA/ROCK pathway inhibitor ameliorates erectile dysfunction induced by radiation therapy in rats

OBJECTIVES

Prostate cancer (PCa) treatment with radiation therapy (RT) has an excellent cure rate. However, Radiation-induced Erectile Dysfunction (RiED) is a common and irreversible toxicity impacting quality of life, and there is no FDA approved specific drug for RiED. We previously showed that prostate RT increased RhoA/ROCK signaling in the cavernous nerve (CN) and penile tissues, which may lead to RiED in rats. In this study, we investigated whether RhoA/ROCK pathway inhibition by a specific inhibitor called Hydroxyfasudil (HF) can improve RiED in our well-established rat model.

MATERIALS/METHODS

Male Sprague-Dawley rats were randomized to the following groups: sham-RT, HF-only, RT-only, and RT + HF. Rats were either exposed to a single dose of 25 Gy prostate-confined RT or a sham procedure. 10 mg/kg HF or normal saline was injected intraperitoneally. Erectile function was evaluated by intracavernosal pressure (ICP) and mean arterial pressure (MAP) measurements at week 14 post-RT. Cavernous nerve (CN) injury was evaluated by transmission electron microscopy (TEM), and penile tissue fibrosis by Masson trichrome staining (MT).

RESULTS

We have found that the HF treatment prior to RT showed significant (p < 0.001) improvement in ICP/MAP ratio, area under the curve, and maximum ICP value, compared to RT-alone rats. Furthermore, RT + HF treated rats exhibited increased CN myelination and decreased axonal atrophy, comparted to RT-only. HF treatment showed significantly decreased penile tissue fibrosis (p < 0.05) compared to RT-alone treated rats.

CONCLUSION

Our results provide the first preclinical evidence that targeting RhoA/ROCK pathway by HF may provide a novel therapeutic option for the treatment of RiED.

Controls to Minimize Disruption of the Pharmaceutical Supply Chain During the COVID-19 Pandemic

This article reviews currently available scientific literature related to the epidemiology, infectivity, survival, and susceptibility to disinfectants of Coronaviruses, in the context of the controls established to meet good manufacturing practice (GMP) regulations and guidance, and the public health guidance issued specifically to combat the COVID-19 pandemic. The possible impact of the COVID-19 pandemic on the pharmaceutical supply chain is assessed and recommendations are listed for risk mitigation steps to minimize supply disruption to pharmaceutical drug products. Areas addressed include a brief history of the COVID-19 viral pandemic, a description of the virus, the regulatory response to the pandemic, the screening of employees, the persistence of the virus on inanimate surfaces, cleaning and disinfection of manufacturing facilities, the use of GMP-mandated personal protective equipment to counter the spread of the disease, the role of air changes in viral clearance, and approaches to risk assessment and mitigation. Biological medicinal products have a great record of safety, yet the cell cultures used for production can be susceptible to viruses, and contamination events have occurred. Studies on SARS-CoV-2 for it ability to replicate in various mammalian cell lines used for biopharmaceutical manufacturing suggests that the virus poses a low risk and any contamination would be detected by currently used adventitious virus testing. The consequences of the potential virus exposure of manufacturing processes as well as the effectiveness of mitigation efforts are discussed. The pharmaceutical supply chain is complex, traversing many geographies and companies that range from large multinationals to mid- and small-size operations. This paper recommends practices that can be adopted by all companies, irrespective of their size, geographic location, or position in the supply chain.

A failure modes and effects analysis quality management framework for image-guided small animal irradiators: A change in paradigm for radiation biology

PURPOSE

Image-guided small animal irradiators (IGSAI) are increasingly being adopted in radiation biology research. These animal irradiators, designed to deliver radiation with submillimeter accuracy, exhibit complexity similar to that of clinical radiation delivery systems, including image guidance, robotic stage motion, and treatment planning systems. However, physics expertise and resources are scarcer in radiation biology, which makes implementation of conventional prescriptive QA infeasible. In this study, we apply the failure modes and effect analysis (FMEA) popularized by the AAPM task group 100 (TG-100) report to IGSAI and radiation biological research.

METHODS

Radiation biological research requires a change in paradigm where small errors to large populations of animals are more severe than grievous errors that only affect individuals. To this end, we created a new adverse effects severity table adapted to radiation biology research based on the original AAPM TG-100 severity table. We also produced a process tree which outlines the main components of radiation biology studies performed on an IGSAI, adapted from the original clinical IMRT process tree from TG-100. Using this process tree, we created and distributed a preliminary survey to eight expert IGSAI operators in four institutions. Operators rated proposed failure modes for occurrence, severity, and lack of detectability, and were invited to share their own experienced failure modes. Risk probability numbers (RPN) were calculated and used to identify the failure modes which most urgently require intervention.

RESULTS

Surveyed operators indicated a number of high (RPN >125) failure modes specific to small animal irradiators. Errors due to equipment breakdown, such as loss of anesthesia or thermal control, received relatively low RPN (12-48) while errors related to the delivery of radiation dose received relatively high RPN (72-360). Errors identified could either be improved by manufacturer intervention (e.g., electronic interlocks for filter/collimator) or physics oversight (errors related to tube calibration or treatment planning system commissioning). Operators identified a number of failure modes including collision between the collimator and the stage, misalignment between imaging and treatment isocenter, inaccurate robotic stage homing/translation, and incorrect SSD applied to hand calculations. These were all relatively highly rated (90-192), indicating a possible bias in operators towards reporting high RPN failure modes.

CONCLUSIONS

The first FMEA specific to radiation biology research was applied to image-guided small animal irradiators following the TG-100 methodology. A new adverse effects severity table and a process tree recognizing the need for a new paradigm were produced, which will be of great use to future investigators wishing to pursue FMEA in radiation biology research. Future work will focus on expanding scope of user surveys to users of all commercial IGSAI and collaborating with manufacturers to increase the breadth of surveyed expert operators.

Accounting for respiratory motion in small serial structures during radiotherapy planning: proof of concept in virtual bronchoscopy-guided lung functional avoidance radiotherapy

Respiratory motion management techniques in radiotherapy (RT) planning are primarily focused on maintaining tumor target coverage. An inadequately addressed need is accounting for motion in dosimetric estimations in smaller serial structures. Accurate dose estimations in such structures are more sensitive to motion because respiration can cause them to move completely in or out of a high dose-gradient field. In this work, we study three motion management strategies (m1-m3) to find an accurate method to estimate the dosimetry in airways. To validate these methods, we generated a 'ground truth' digital breathing model based on a 4DCT scan from a lung stereotactic ablative radiotherapy (SAbR) patient. We simulated 225 breathing cycles with  ±10% perturbations in amplitude, respiratory period, and time per respiratory phase. A high-resolution breath-hold CT (BHCT) was also acquired and used with a research virtual bronchoscopy software to autosegment 239 airways. Contours for planning target volume (PTV) and organs at risk (OARs) were defined on the maximum intensity projection of the 4DCT (CT_MIP) and transferred to the average of the 10 4DCT phases (CT_AVG). To design the motion management methods, the RT plan was recreated using different images and structure definitions. Methods m1 and m2 recreated the plan using the CT_AVG image. In method m1, airways were deformed to the CT_AVG. In m2, airways were deformed to each of the 4DCT phases, and union structures were transferred onto the CT_AVG. In m3, the RT plan was recreated on each of the 10 phases, and the dose distribution from each phase was deformed to the BHCT and summed. Dose errors (mean [min, max]) in airways were: m1: 21% (0.001%, 93%); m2: 45% (0.1%, 179%); and m3: 4% (0.006%, 14%). Our work suggests that accurate dose estimation in moving small serial structures requires customized motion management techniques (like m3 in this work) rather than current clinical and investigational approaches.

Development and prospective in-patient proof-of-concept validation of a surface photogrammetry + CT-based volumetric motion model for lung radiotherapy

PURPOSE

We develop and validate a motion model that uses real-time surface photogrammetry acquired concurrently with four-dimensional computed tomography (4DCT) to estimate respiration-induced changes within the entire irradiated volume, over arbitrarily many respiratory cycles.

METHODS

A research, couch-mounted, VisionRT (VRT) system was used to acquire optical surface data (15 Hz, ROI = 15 × 20 cm² ) from the thoraco-abdominal surface of a consented lung SBRT patient, concurrently with their standard-of-care 4DCT. The end-exhalation phase from the 4DCT was regarded as reference and for each remaining phase, deformation vector fields (DVFs) with respect to the reference phase were computed. To reduce dimensionality, the first two principal components (PCs) of the matrix of nine DVFs were calculated. In parallel, ten phase-averaged VRT surfaces were created. Surface DVFs and corresponding PCs were computed. A principal least squares regression was used to relate the PCs of surface DVF to those of volume DVFs, establishing a relationship between time-varying surface and the underlying time-varying volume. Proof-of-concept validation was performed during each treatment fraction by concurrently acquiring 30 s time series of real-time surface data and "ground truth" kV fluoroscopic data (FL). A ray-tracing algorithm was used to create a digitally reconstructed fluorograph (DRF), and motion trajectories of high-contrast, soft-tissue, anatomical features in the DRF were compared with those from kV FL.

RESULTS

For five of the six fluoroscopic acquisition sessions, the model out-performed 4DCT in predicting contour Dice coefficient with respect to fluoroscopy-derived contours. Similarly, the model exhibited a marked improvement over 4DCT for patch positions on the diaphragm. Model patch position errors varied from 5 to -15 mm while 4DCT errors ranged between 5 and -22.4 mm. For one fluoroscopic acquisition, a marked change in the a priori internal-external correlation resulted in model errors comparable to those of 4DCT.

CONCLUSIONS

We described the development and a proof-of-concept validation for a volumetric motion model that uses surface photogrammetry to correlate the time-varying thoraco-abdominal surface to the time-varying internal thoraco-abdominal volume. These early results indicate that the proposed approach can result in a marked improvement over 4DCT. While limited by the duration of the fluoroscopic acquisitions as well as the resolution of the acquired images, the DRF-based proof-of-concept technique developed here is model-agnostic, and therefore, has the potential to be used as an in-patient validation tool for other volumetric motion models.

Inverse radiotherapy planning based on bioeffect modelling for locally advanced left-sided breast cancer

BACKGROUND AND PURPOSE

Treatment planning of radiotherapy (RT) for left-sided breast cancer is a challenging case. Several competing concerns are incorporated at present through protocol-defined dose-volume constraints, e.g. cardiac exposure and target coverage. Such constraints are limited by neglecting patient-specific risk factors (RFs). We propose an alternative RT planning method based solely on bioeffect models to minimize the estimated risks of breast cancer recurrence (BCR) and radiation-induced mortality endpoints considering patient-specific factors.

METHODS AND MATERIALS

Thirty-nine patients with left-sided breast cancer treated with comprehensive post-lumpectomy loco-regional conformal RT were included. An in-house particle swarm optimization (PSO) engine was used to choose fields from a large set of predefined fields and optimize monitor units to minimize the total risk of BCR and mortality caused by radiation-induced ischaemic heart disease (IHD), secondary lung cancer (SLC) and secondary breast cancer (SBC). Risk models included patient age, smoking status and cardiac risk and were developed using published multi-institutional data.

RESULTS

For the clinical plans the normal tissue complication probability, i.e. summed risk of IHD, SLC and SBC, was <3.7% and the risk of BCR was <6.1% for all patients. Median total decrease in mortality or recurrence achieved with individualized PSO plans was 0.4% (range, 0.06-2.0%)/0.5% (range, 0.11-2.2%) without/with risk factors.

CONCLUSIONS

Inverse RT plan optimization using bioeffect probability models allows individualization according to patient-specific risk factors. The modelled benefit when compared to clinical plans is, however, modest in most patients, demonstrating that current clinical plans are close to optimal. Larger gains may be achievable with morbidity endpoints rather than mortality.

A novel deformable lung phantom with programably variable external and internal correlation

PURPOSE

Lung motion phantoms used to validate radiotherapy motion management strategies have fairly simplistic designs that do not adequately capture complex phenomena observed in human respiration such as external and internal deformation, variable hysteresis and variable correlation between different parts of the thoracic anatomy. These limitations make reliable evaluation of sophisticated motion management techniques quite challenging. In this work, we present the design and implementation of a programmable, externally and internally deformable lung motion phantom that allows for a reproducible change in external-internal and internal-internal correlation of embedded markers.

METHODS

An in-house-designed lung module, made from natural latex foam was inserted inside the outer shell of a commercially available lung phantom (RSD, Long Beach, CA, USA). Radiopaque markers were placed on the external surface and embedded into the lung module. Two independently programmable high-precision linear motion actuators were used to generate primarily anterior-posterior (AP) and primarily superior-inferior (SI) motion in a reproducible fashion in order to enable (a) variable correlation between the displacement of interior volume and the exterior surface, (b) independent changes in the amplitude of the AP and SI motions, and (c) variable hysteresis. The ability of the phantom to produce complex and variable motion accurately and reproducibly was evaluated by programming the two actuators with mathematical and patient-recorded lung tumor motion traces, and recording the trajectories of various markers using kV fluoroscopy. As an example application, the phantom was used to evaluate the performance of lung motion models constructed from kV fluoroscopy and 4DCT images.

RESULTS

The phantom exhibited a high degree of reproducibility and marker motion ranges were reproducible to within 0.5 mm. Variable correlation was observed between the displacements of internal-internal and internal-external markers. The SI and AP components of motion of a specific marker had a correlation parameter that varied from -11 to 17. Monitoring a region of interest on the phantom's surface to estimate internal marker motion led to considerably lower uncertainties than when a single point was monitored.

CONCLUSIONS

We successfully designed and implemented a programmable, externally and internally deformable lung motion phantom that allows for a reproducible change in external-internal and internal-internal correlation of embedded markers.

Technical Note: In silico and experimental evaluation of two leaf-fitting algorithms for MLC tracking based on exposure error and plan complexity

PURPOSE

Multileaf collimator (MLC) tracking is being clinically pioneered to continuously compensate for thoracic and pelvic motion during radiotherapy. The purpose of this work was to characterize the performance of two MLC leaf-fitting algorithms, direct optimization and piecewise optimization, for real-time motion compensation with different plan complexity and tumor trajectories.

METHODS

To test the algorithms, both in silico and phantom experiments were performed. The phantom experiments were performed on a Trilogy Varian linac and a HexaMotion programmable motion platform. High and low modulation VMAT plans for lung and prostate cancer cases were used along with eight patient-measured organ-specific trajectories. For both MLC leaf-fitting algorithms, the plans were run with their corresponding patient trajectories. To compare algorithms, the average exposure errors, i.e., the difference in shape between ideal and fitted MLC leaves by the algorithm, plan complexity and system latency of each experiment were calculated.

RESULTS

Comparison of exposure errors for the in silico and phantom experiments showed minor differences between the two algorithms. The average exposure errors for in silico experiments with low/high plan complexity were 0.66/0.88 cm² for direct optimization and 0.66/0.88 cm² for piecewise optimization, respectively. The average exposure errors for the phantom experiments with low/high plan complexity were 0.73/1.02 cm² for direct and 0.73/1.02 cm² for piecewise optimization, respectively. The measured latency for the direct optimization was 226 ± 10 ms and for the piecewise algorithm was 228 ± 10 ms. In silico and phantom exposure errors quantified for each treatment plan demonstrated that the exposure errors from the high plan complexity (0.96 cm² mean, 2.88 cm² 95% percentile) were all significantly different from the low plan complexity (0.70 cm² mean, 2.18 cm² 95% percentile) (P < 0.001, two-tailed, Mann-Whitney statistical test).

CONCLUSIONS

The comparison between the two leaf-fitting algorithms demonstrated no significant differences in exposure errors, neither in silico nor with phantom experiments. This study revealed that plan complexity impacts the overall exposure errors significantly more than the difference between the algorithms.

Mild hyperthermia as a localized radiosensitizer for deep-seated tumors: investigation in an orthotopic prostate cancer model in mice

OBJECTIVE:

Non-ablative or mild hyperthermia (HT) has been shown in preclinical (and clinical) studies as a localized radiosensitizer that enhances the tumoricidal effects of radiation. Most preclinical in vivo HT studies use subcutaneous tumor models which do not adequately represent clinical conditions (e.g. proximity of normal/critical organs) or replicate the tumor microenvironment-both of which are important factors for eventual clinical translation. The purpose of this work is to demonstrate proof-of-concept of locoregional radiosensitization with superficially applied, radiofrequency (RF)-induced HT in an orthotopic mouse model of prostate cancer.

METHODS:

In a 4-arm study, 40 athymic male nude mice were inoculated in the prostate with luciferase-transfected human prostate cancer cells (PC3). Tumor volumes were allowed to reach 150-250 mm3 (as measured by ultrasound) following which, mice were randomized into (i) control (no intervention); (ii) HT alone; (iii) RT alone; and (iv) HT + RT. RF-induced HT was administered (Groups ii and iv) using the Oncotherm LAB EHY-100 device to achieve a target temperature of 41 °C in the prostate. RT was administered ~30 min following HT, using an image-guided small animal radiotherapy research platform. In each case, a dual arc plan was used to deliver 12 Gy to the target in a single fraction. One animal from each cohort was euthanized on Day 10 or 11 after treatment for caspase-9 and caspase-3 Western blot analysis.

RESULTS:

The inoculation success rate was 89%. Mean tumor size at randomization (~16 days post-inoculation) was ~189 mm3 . Following the administration of RT and HT, mean tumor doubling times in days were: control = 4.2; HT = 4.5; RT = 30.4; and HT + RT = 33.4. A significant difference (p = 0.036) was noted between normalized nadir volumes for the RT alone (0.76) and the HT + RT (0.40) groups. Increased caspase-3 expression was seen in the combination treatment group compared to the other treatment groups.

CONCLUSION:

These early results demonstrate the successful use of external mild HT as a localized radiosensitizer for deep-seated tumors.

ADVANCES IN KNOWLEDGE:

We successfully demonstrated the feasibility of administering external mild HT in an orthotopic tumor model and demonstrated preclinical proof-of-concept of HT-based localized radiosensitization in prostate cancer radiotherapy.

A comprehensive geometric quality assurance framework for preclinical microirradiators

PURPOSE

The mechanical and geometric accuracy of small animal image-guided radiotherapy (SA-IGRT) systems is critical and is affected by a number of system-related factors. Because of the small dimensions involved in preclinical radiotherapy research, such factors can individually and/or cumulatively contribute to significant errors in the small animal radiation research. In this study, we developed and implemented a comprehensive quality assurance (QA) framework for characterizing the mechanical and geometric constancy and accuracy of the small animal radiation research platform (SARRP) system.

METHODS

We quantified the accuracy of gantry and stage rotation isocentricity and positional stage translations. We determined the accuracy and symmetry of field sizes formed by collimators. We evaluated collimator assembly system performance by characterization of collimator axis alignment along the beam axis during gantry rotation. Furthermore, we quantified the end-to-end precision and accuracy of image-guided delivery by examining the congruence of intended (e.g., imaging) and actual delivery (measured during experiment) isocenters.

RESULTS

The fine and broad beams showed different central axes. The center of the beam was offset toward the cathode (0.22 ± 0.05 mm) when switching the beam from a fine to a broad focus. Larger (custom-made) collimators were more symmetrically centered than smaller (standard) collimators. The field formed by a 1-mm circular collimator was found to deviate from the circular shape, measuring 1.55 mm and 1.25 mm in the X and Y directions, respectively. The 40-mm collimator showed a field that was 1.65 (4.13%) and 1.3 (3.25%) mm smaller than nominal values in the X and Y directions, respectively, and the 30-mm collimator field was smaller by 0.75 mm (2.5%) in the X direction. Results showed that fields formed by other collimators were accurate in both directions and had ≤2% error. The size of the gantry rotation isocenter was 1.45 ± 0.15 mm. While the gantry rotated, lateral and longitudinal isocenter displacements ranged from 0 to -0.34 and -0.44 to 0.33 mm, respectively. Maximum lateral and longitudinal displacements were found at obliques gantry angles of -135° and 45°, respectively. The stage translational accuracies were 0.015, 0.010, and 0 mm in the X, Y, and Z directions, respectively. The size of the stage rotation runout was 2.73 ± 0.3 mm. Maximum displacements of the stage rotational axis were -0.38 (X direction) and -0.26 (Y direction) mm at stage angles of -45° and -135°, respectively. We found that displacements of intended and actual delivery isocenters were 0.24 ± 0.10, 0.12 ± 0.62, and 0.12 ± 0.42 mm in the X, Y, and Z directions, respectively.

CONCLUSION

We used the SARRP built-in electronic portal imaging device (EPID) to perform most of the geometric QA tests, demonstrating the utility of the EPID for characterizing the geometric accuracy and precision of the SA-IGRT system. However, in principle, the methodology and tests developed here are applicable to any digital imaging detector available in SA-IGRT systems or film. The flexibility of film allows these tests to be adapted for QA of non-IGRT, cabinet irradiators, which make up many of preclinical small animal irradiators.

Inverse-planned deliverable 4D-IMRT for lung SBRT

PURPOSE

We present a particle swarm optimization (PSO)-based technique to create deliverable four-dimensional (4D = 3D + time) intensity-modulated radiation therapy (IMRT) plans for lung stereotactic body radiotherapy (SBRT). The 4D planning concept uses respiratory motion as an additional degree of freedom to achieve further sparing of organs at risk (OARs). The 4D-IMRT plan involves the delivery of an order of magnitude more IMRT apertures (~15,000-20,000), with potentially large interaperture variations in the delivered fluence, compared to conventional (i.e., 3D) IMRT. In order to deliver the 4D plan in an efficient manner, we present an optimization-based aperture sequencing technique.

METHOD

A graphic processing unit (GPU)-enabled PSO-based inverse planning engine, developed and integrated with a research version of the Eclipse (Varian, Palo Alto, CA) treatment planning system (TPS), was employed to create 4D-IMRT plans as follows. Four-dimensional computed tomography scans (4DCTs) and beam configurations from clinical treatment plans of seven lung cancer patients were retrospectively collected, and in each case, the PSO engine iteratively adjusted aperture monitor unit (MU) weights for all beam apertures across all respiratory phases to optimize OAR dose sparing while maintaining planning target volume (PTV) coverage. We calculated the transition times from each aperture to all other apertures for each beam, taking into account the maximum leaf velocity of the multileaf collimator (MLC), and developed a mixed integer optimization technique for aperture sequencing. The goal of sequencing was to maximize delivery efficiency (i.e., minimize the time required to deliver the dose map) by accounting for leaf velocity, aperture MUs, and duration of each respiratory phase. The efficiency of the proposed delivery method was compared with that of a greedy algorithm which chose only from neighboring apertures for the subsequent steps in the sequence.

RESULTS

4D-IMRT-optimized plans achieved PTV coverage comparable to clinical plans while improving OAR sparing by an average of 39.7% for D max heart, 20.5% for D max esophagus, 25.6% for D max spinal cord, and 2.1% for V 13 lung (with D max standing for maximum dose and V 13 standing for volume receiving ≥ 13 Gy). Our mixed integer optimization-based aperture sequencing enabled the delivery to be performed in fewer cycles compared to the greedy method. This reduction was 89 ± 79 cycles corresponding to an improvement of 15.94 ± 8.01%, when considering respiratory cycle duration of 4 s, and 55 ± 33 cycles corresponding to an improvement of 15.14 ± 4.45%, when considering respiratory cycle duration of 6 s.

CONCLUSION

PSO-based 4D-IMRT represents an attractive technique to further improve OAR sparing in lung SBRT. Efficient delivery of a large number of sparse apertures (control points) introduces a challenge in 4D-IMRT treatment planning and delivery. Through judicious optimization of the aperture sequence across all phases, such delivery can be performed on a clinically feasible time scale.